Cir S.p.a. - Compagnie Industriali Riunite · MIL:CIR

Cir S.p.a. - Compagnie Industriali Riunite — CIR S.p.A. - Compagnie Industriali Riunite — Q1 2020 Earnings Presentation

22 slides from Cir S.p.a. - Compagnie Industriali Riunite's earnings presentation, April 2020

  1. Slide 1: 1Q 2020 Results

    CIR 1Q 2020 Results April 2020 777777 y ARRBREE EE LETT aga 1 93 SF ELEN eee ESS aaa ry ye TFS eee epeteetaaae: PPP IsIsF a oe Caan ; ; Seagaaetad Dy eeaa 64450en PP; 2D yyy, wr

  2. Slide 2: New CIR: streamlined group structure and renewed strategic focus

    New CIR: streamlined group structure and renewed strategic focus • • •

  3. Slide 3: New CIR: streamlined group structure

    New CIR: streamlined group structure

  4. Slide 4: New CIR: merger of CIR into Cofide completed

    New CIR: merger of CIR into Cofide completed • • •

  5. Slide 5: New CIR: disposal of GEDI completed

    New CIR: disposal of GEDI completed • • • •

  6. Slide 6: CIR: 1Q 2020 financial highlights

    CIR: 1Q 2020 financial highlights • • • • •

  7. Slide 7: CIR Group Consolidated income statement

    CIR Group Consolidated income statement • • • •

  8. Slide 8: CIR Group Consolidated income statement by business

    CIR Group Consolidated income statement by business €/M

  9. Slide 9: CIR Group - Consolidated balance sheet

    CIR Group - Consolidated balance sheet

  10. Slide 10: KOS – A leading operator in Long Term Care

    KOS – A leading operator in Long Term Care ≈ SHAREHOLDERS ▪ CIR (59.53%) ▪ F2i (40.47%) LONG TERM CARE DIAGNOSTICS & CANCER CARE ACUTE CARE o REHABILITATION NURSING HOMES NURSING HOMES & PSYCHIATRY (ITALY) (ITALY) (GERMANY) • ≈30 Service Contracts • 1 Hospital • 36 facilities • 52 facilities • 48 fa

  11. Slide 11: KOS – A geographically diversified player

    KOS – A geographically diversified player 2019 Pro Forma(1) Revenues 2019 Pro Forma(1) Revenues split (%) (€m) 22% 538 1% Fussen 3% Italy 2019 A 74% 156 Germany 2019 PF(1) 21 Milano New Delhi India 2019 A 10 London 2019 A UK Long Term Care site Diagnostics & Cancer Care site Headquarter (1) 2019 Ful

  12. Slide 12: KOS – Growth strategy and track record

    KOS – Growth strategy and track record • Long • Term Care • Diagnos- • tics & Cancer • Care

  13. Slide 13: KOS – 2019 P&L by business

    KOS — 2019 P&L by business €/M Number of beds Number of beds under construction/acquired Revenues EBITDAR EBITDA EBITDA w/o IFRS16 EBIT EBITDAR margin EBIT margin IRE Assets Book Value 21,2 IRE Assets Fair Value 270,5 IRE Debt w/o IFRS16 (80,9) 8.406 1.236 492,2 78,3 (2,4) 123,8 23,1 (3,7) 120,6 22,

  14. Slide 14: KOS – 1Q 2020 performance

    KOS – 1Q 2020 performance • • • • • •

  15. Slide 15: KOS – Acquisition of Charleston in Germany

    KOS – Acquisition of Charleston in Germany • • • •

  16. Slide 16: Sogefi – overview

    Sogefi – overview Key financials 1H 201 SUSPENSIONS FILTRATION AIR & COOLING 36% 36% 28% • 11.7% Europe 60.9% 11.2% North America 19.0% • FORD 10.7% South America 10.5% FCA/CNH Industrial 10.1% Asia 9.6% GM 8.1% • DAIMLER 7.6% VOLKSWAGEN/AUDI 5.0% Weight of non-European markets: 39% TOYOTA 3.2% BMW

  17. Slide 17: CIR Group - Consolidated net financial position

    CIR Group - Consolidated net financial position €/M • •

  18. Slide 18: Net financial position at CIR Holding level

    Net financial position at CIR Holding level • (€ m) (1) (2) (3) Net financial surplus at Dec. 31, Net investments Fair value adjustment Holding costs Net financial surplus at March 31, 2019 2020 (1) Private equity investments (2) Delta fair value of securities + securities income (loss), trading (3)

  19. Slide 19: Composition of net financial position at CIR Holding level

    Composition of net financial position at CIR Holding level €/M

  20. Slide 20: Non-core investments

    Non-core investments Private equity * Diversified portfolio of private equity funds and direct minority private equity investments, with a fair value of € 59.2 M at 31 March 2020 (+ € 0.9 Mas a result of net investments) * The portfolio has reached its maturity/reimbursement phase, as limited invest

  21. Slide 21: Disclaimer

    Disclaimer | This document has been prepared by CIR for information purposes only and for use in presentations of the Group’s results and strategies. For further details on CIR and its Group, reference should be made to publicly available information, including the Annual Report, the Semi-Annual and

  22. Slide 22: CIR

    CIR www.cirgroup.com

CIR S.p.A. - Compagnie Industriali Riunite — Q1 2020 Earnings Presentation on 6ix